This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Goldenberg, V. K. Articles by Lipkus, I. M. Search for Related Content PubMed PubMed Citation Articles by Goldenberg, V. K. Articles by Lipkus, I. M. Related Collections Behavioral Science Behavioral Science: Interventions: Behavioral, Pharmacologic, Pharmacogenetic

Atypia in Random Periareolar Fine-Needle Aspiration Affects the Decision of Women at High Risk to Take Tamoxifen for Breast Cancer Chemoprevention

¹ Duke University Medical Center, Durham, North Carolina; ² University of Kansas Medical Center, Kansas City, Kansas; and ³ Yale-New Haven Medical Center, New Haven, Connecticut

Requests for reprints: Isaac M. Lipkus, 905 West Main Street, Box 34, Durham, NC 27701. Phone: 919-956-5232; Fax: 919-956-7451; E-mail: lipku001{at}mc.duke.edu

Random periareolar fine-needle aspiration (RPFNA) is a research procedure designed to (a) evaluate short-term breast cancer risk in women at high risk for developing breast cancer, and (b) track response to chemoprevention. Of import, cellular atypia in breast RPFNA is prospectively associated with a 5.6-fold increase in breast cancer risk in women at high risk. Among 99 women attending a clinic for high-risk breast cancer, we explored the effects of RPFNA cytology results on decision making pertaining to the use of tamoxifen for breast cancer chemoprevention. No patient with nonproliferative or hyperplastic cytology subsequently elected to take tamoxifen. Only 7% of subjects with borderline atypia elected to take tamoxifen. In contrast, 50% with atypia elected to take tamoxifen. These results suggest that the provision of a biomarker of short-term risk can affect the motivation to take tamoxifen for chemoprevention. This conclusion is informative given that tamoxifen, due to its side effects, is often underused by women at high risk of developing breast cancer. Further research is needed to determine the mechanisms through which RPFNA results affect the decision to use tamoxifen, or any other breast cancer chemopreventive agent. (Cancer Epidemiol Biomarkers Prev 2007;16(5):1032–4)

This article has been cited by other articles:

				G. Rondanina, M. Puntoni, G. Severi, C. Varricchio, A. Zunino, I. Feroce, B. Bonanni, and A. Decensi Psychological and Clinical Factors Implicated in Decision Making About a Trial of Low-Dose Tamoxifen in Hormone Replacement Therapy Users J. Clin. Oncol., March 20, 2008; 26(9): 1537 - 1543. [Abstract] [Full Text] [PDF]